Elemental Impurities (ICH Q3D): Replacing the Heavy Metals Test With a Risk Assessment
The old colorimetric "heavy metals" limit test could not tell lead from copper. ICH Q3D swapped it for element-specific exposure limits and a documented risk assessment, which changed how every formulation gets reviewed.
01Why a risk assessment replaced a limit test
Metals do not appear in a medicine because anyone wants them there. They arrive through catalysts, mined excipients, water, manufacturing equipment and container closure systems, and the question is whether the total exposure stays under a toxicologically justified ceiling.
ICH Q3D moved control from a non-specific heavy metals test to a scientifically based risk assessment, with element-specific permitted daily exposures (PDEs) and modern analytical techniques such as ICP-OES and ICP-MS.5,7 A PDE is the maximum daily intake of an element considered unlikely to cause harm, and each one is derived from toxicology data scaled to a 50 kg patient.1,2
This is the third impurity framework in the series' recent run, after nitrosamines and extractables and leachables, and it follows the same logic: assess risk first, test where the assessment says it matters, and document why the result is acceptable.
Measuring Elemental Impurities in Pharmaceuticals: A Practical Guide — Robert Thomas
Written specifically for this topic: it covers ICP-MS and ICP-OES principles, sample preparation and the risk assessment approach, aimed at analysts who are new to elemental impurities testing.
Find it on Amazon →02The regulatory foundations
| Framework | Issuing body | Core contribution |
|---|---|---|
| ICH Q3D(R2) — Guideline for Elemental Impurities | International Council for Harmonisation | Sets PDEs by route of administration and the risk assessment process1,2 |
| USP General Chapters <232> and <233> | United States Pharmacopeia | Align limits with Q3D and describe procedures for measuring elemental impurities7 |
| ICH Q9 — Quality Risk Management | International Council for Harmonisation | Principles Q3D explicitly tells manufacturers to apply when controlling elemental impurities6 |
The (R2) revision adds updated cutaneous and transcutaneous considerations, and its text still works through the same PDE-based logic and the same concentration-limit options as earlier versions.1,2,3
03The three-step risk assessment
ICH Q3D lays out a three-step risk assessment that applies to each drug product.5 Click each step to expand it.
List the places an element could enter: the drug substance and its synthesis, excipients, manufacturing equipment, water, and the container closure system.
- Intentionally added catalysts and reagents are the highest-priority sources
- Supplier data feeds this step, linking back to the supplier qualification post
Determine measured or predicted levels from each contributor and compare the total to the PDE. A control threshold, defined as 30% of the PDE, is used to decide whether further control is warranted.1,6
- Calculation uses the actual maximum daily dose of the product
- Levels can be predicted from supplier data or confirmed by testing
Summarize the assessment, justify the conclusion, and put a control strategy in place where levels could approach the PDE.
- Changes to materials or suppliers feed back through change control
- The assessment is a living document, revisited when inputs change
Quality Risk Management in the FDA-Regulated Industry — José Rodriguez-Perez
Q3D tells manufacturers to follow ICH Q9 principles. This book covers the risk tools used to document the source-by-source assessment in steps 1 and 2 above.
Find it on Amazon →04Element classes
Q3D sorts elements by toxicity and by how likely they are to appear in a drug product. Switch tabs to compare the classes.
Class 1: arsenic, cadmium, mercury, lead. Highly toxic, and always part of the risk assessment regardless of route. Oral PDEs are As 15, Cd 5, Hg 30 and Pb 5 µg/day.1,2
Class 2A: cobalt, nickel, vanadium. Route-dependent toxicants with a relatively high likelihood of occurring in drug products, so they are included in the risk assessment by default.
Class 2B: silver, gold, iridium, osmium, palladium, platinum, rhodium, ruthenium, selenium, thallium. Route-dependent but with low likelihood of occurring, so they only need to be assessed when intentionally added, for example as catalysts. A published excipient survey supported that approach.4
Class 3: barium, chromium, copper, lithium, molybdenum, antimony, tin. Relatively low toxicity by the oral route, so the assessment is generally needed only for parenteral and inhalation products unless there is a specific concern.
05PDE concentration limit calculator
For products with a daily intake of 10 g or less, Q3D's Option 1 turns a PDE into a common concentration limit by dividing by 10 g. More generally, the limit for a given dose is the PDE divided by the daily dose in grams.1,6 Enter your own dose, plus a measured level if you have one.
PDE-to-concentration converter interactive
Limit (µg/g) = PDE (µg/day) ÷ daily dose (g/day). Exposure (µg/day) = measured level (µg/g) × daily dose (g/day). The control threshold is 30% of the PDE. Oral Class 1 PDEs are preset.
This is a simplified single-element illustration. A real assessment sums contributions from every component, accounts for the route of administration, and uses current PDE tables from the official ICH Q3D text. Option 1 is only appropriate for products with a daily intake of 10 g or less. Never rely on this tool alone for a compliance decision.
Handbook of Analytical Validation — Michael E. Swartz & Ira S. Krull
When testing replaces prediction, the ICP method itself has to be validated for accuracy, precision and quantitation limits at the levels in the table above. This is the validation reference used in the analytical method validation post.
Find it on Amazon →06Elemental impurities self-check
Readiness checklist
07Where programs fail inspection
- Assuming the old heavy metals test still counts. A pass on the legacy test says little about element-specific exposure and does not replace a Q3D assessment.
- Using the 10 g default for a high-dose product. Option 1 assumes a daily intake of 10 g or less, so a high-dose liquid or powder needs a calculation based on its actual dose.
- Forgetting the container closure system. Packaging components are a recognized source, which links this work to the packaging and extractables posts earlier in the series.
- Ignoring intentionally added catalysts. Class 2B elements are only exempt from assessment when nobody added them on purpose, so a palladium catalyst in the synthesis puts palladium back in scope.4
08Specimen quality forms
An elemental impurities risk assessment summary and a testing record, the two documents that typically anchor a Q3D file.
Form EI-01 — Elemental Impurities Risk Assessment Summary
Specimen only — not a controlled document. Attach supplier statements and calculations as appendices.
| Source | Elements of concern | Estimated level | % of PDE |
|---|---|---|---|
| Drug substance | |||
| Excipients | |||
| Manufacturing equipment / water | |||
| Container closure system |
Form EI-02 — Elemental Impurities Testing Record
Specimen only — for recording ICP results against the PDE-derived limit.
| Batch / material | Element | Result (µg/g) | Limit (µg/g) | Pass / Fail |
|---|---|---|---|---|
These specimen forms illustrate typical content only. Your quality system's document control procedure takes precedence over this format.
Pharmaceutical Packaging Technology — D.A. Dean, E.R. Evans & I.H. Hall (Eds.)
Container closure systems are one of the recognized sources in step 1 of the risk assessment. This book covers the glass, plastic and elastomer materials that make up those systems.
Find it on Amazon →09References
- International Council for Harmonisation. Guideline for Elemental Impurities Q3D(R2). Step 4, 2022. database.ich.org
- European Medicines Agency. ICH Guideline Q3D (R2) on Elemental Impurities — Step 5. ema.europa.eu
- European Medicines Agency. ICH Guideline Q3D (R1) on Elemental Impurities — Step 5. ema.europa.eu
- Journal of Pharmaceutical Sciences. "Elemental Impurities in Pharmaceutical Excipients." 2015. jpharmsci.org
- Torres S., Boetzel R., et al. "ICH Q3D Drug Product Elemental Risk Assessment: The Use of an Elemental Impurities Excipients Database." Journal of Pharmaceutical Sciences, 2022. sciencedirect.com
- IntuitionLabs. "ICH Q3D Elemental Impurities: Risk Assessment Guide." intuitionlabs.ai
- Elemental Analysis. "A Practical Guide to Elemental Impurities Testing and FDA Guidelines." elementalanalysis.com
No comments:
Post a Comment